327 results on '"Frumovitz, Michael"'
Search Results
2. Other rare cervical cancers: cervical rhabdomyosarcoma, adenoid cystic carcinoma, verrucous carcinoma
3. Contributors
4. High grade neuroendocrine carcinoma of the cervix
5. Innovations in Rare Gynecologic Cancer: Melanoma, Neuroendocrine, and Low-Grade Serous Ovarian
6. Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors
7. Special considerations
8. List of contributors
9. Techniques in Gynecologic Oncology
10. Neoplastic diseases of the vulva and vagina
11. Molecular image–guided surgery in gynaecological cancer: where do we stand?
12. YAP1 status defines two intrinsic subtypes of LCNEC with distinct molecular features and therapeutic vulnerabilities
13. Uncommon Gynecologic Cancers
14. PET/CT scan improves detection of metastatic disease compared with CT scan alone in women with high-grade neuroendocrine cervical cancer: a NeCTuR study
15. Social media use is associated with higher levels of anxiety and depression in patients with neuroendocrine carcinoma of the cervix: A NeCTuR study
16. Comparing long-term sexual dysfunction across different uterine cancer treatment modalities
17. #657 Global survey on training in sentinel lymph node mapping for endometrial and cervical cancer
18. Clinicopathologic characteristics, oncologic outcomes, and prognostic factors in neuroendocrine cervical carcinoma: a Neuroendocrine Cervical Tumor Registry study
19. 33 The impact of social media on anxiety and depression among patients with neuroendocrine carcinoma of the cervix: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study
20. Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms
21. Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers
22. Abstract CT218: A phase II trial of niraparib plus dostarlimab in relapsed small cell lung cancer and other high-grade neuroendocrine carcinomas
23. Extrauterine Mesonephric-like Carcinoma
24. Secondary Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy for Advanced or Recurrent Mucinous Ovarian Cancer
25. Abstract 4525: YAP1 in relapsed pulmonary high-grade neuroendocrine carcinomas (NEC) is associated with CDKN2A loss, intact RB1, EMT and therapeutic vulnerability to MEK1 and CDK4/6 inhibition
26. Table S6 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer
27. Table S6 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer
28. Table S1, Table S2, Table S3, Table S5 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer
29. Table S4 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer
30. Figure S1, S2, S3, S4 and S5 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer
31. Figure S1, S2, S3, S4 and S5 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer
32. Table S4 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer
33. Table S1, Table S2, Table S3, Table S5 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer
34. Data from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer
35. Data from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer
36. Figure S1 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
37. Figure_S6 from Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer
38. Supplemental Table 2. Distribution of primary vulvar melanomas with tumor thickness > 4.00 mm reported in literature. from Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases
39. Figure S2 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
40. Figure S6 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
41. Figure S4 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
42. Figure S5 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
43. Figure S4 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
44. Figure S2 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
45. Figure S5 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
46. Figure S3 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
47. Supplementary Tables from Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer
48. Supplemental Figure Legend from Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases
49. Supplementary Table 1. Associations between clinical and histopathologic parameters are metastasis (Fisher's exact tests). from Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases
50. Figure S6 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.